MetaCap

Aurinia Pharmaceuticals (AUPH) vs Lakefront Biotherapeutics (LKFT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lakefront Biotherapeutics (LKFT) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 8.6% versus a loss of 6.3%. Over five years, AUPH leads with a -24.0% price change compared with -31.8% for LKFT. Lakefront Biotherapeutics is the larger company by market cap ($2.18 billion vs $1.97 billion), about 1.1 times the size.

On valuation, Lakefront Biotherapeutics trades at a lower trailing P/E (2.4x vs 6.4x for Aurinia Pharmaceuticals).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUPH-6.25%LKFT+8.64%
+20%+2%-17%
Nov 21, 20251 yearNov 20, 2026
AUPH-48.37%LKFT-35.27%
+42%-24%-91%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUPH versus LKFT key metrics
MetricAUPHLKFT
Share price$14.70$33.31
Market cap$1.97B$2.18B
1-day change-1.28%-0.24%
YTD return-7.84%+1.87%
1-year return-6.25%+8.64%
5-year return-23.95%-31.80%
P/E ratio (TTM)6.452.39
Forward P/E12.67—
EPS (TTM)$2.28$13.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$283.06M—
Revenue growth (YoY)+20.38%—
Net income (latest FY)$287.20M—
Gross margin88.46%—
Operating margin37.06%—
Net margin101.47%—
52-week high$19.25$36.24
52-week low$13.52$25.68
Distance from 52-week high-23.64%-8.08%
Analyst consensusbuyhold
Avg. price target upside+25.85%-7.39%
Average volume858.74K280.49K
Shares outstanding134.00M65.48M
Employees128196
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LKFT has outperformed AUPH by 14.9 percentage points over the past year.
  • Aurinia Pharmaceuticals trades at a higher earnings multiple (6.4x vs 2.4x trailing P/E).

About Aurinia Pharmaceuticals

AUPH stock →

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Lakefront Biotherapeutics

LKFT stock →

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees

AUPH vs LKFT FAQ

Which is bigger, Aurinia Pharmaceuticals or Lakefront Biotherapeutics?

Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $2.18B compared with $1.97B for Aurinia Pharmaceuticals (AUPH).

Which stock has performed better over the past year, AUPH or LKFT?

LKFT returned +8.64% over the past 12 months, compared with -6.25% for AUPH (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, AUPH or LKFT?

LKFT has the lower trailing P/E at 2.4, versus 6.4 for AUPH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Aurinia Pharmaceuticals and Lakefront Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons